NMRA — Neumora Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1885522 ·
Last close
$0.48
Market Cap
$90.15M
52W High
$3.65
52W Low
$0.45
ADV30
1,724,320
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -42,190,000 | -43,082,000 | 125,249,000 | 116,834,000 | 80,730,000 |
| Mar 2026 | 0 | — | -52,864,000 | -53,458,000 | 153,877,000 | 147,072,000 | 83,197,000 |
| Dec 2025 | 0 | — | -58,480,000 | -59,450,000 | 191,047,000 | 182,530,000 | 87,176,000 |
| Sep 2025 | 0 | — | -57,700,000 | -56,755,000 | 177,833,000 | 129,071,000 | 45,672,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-193,396,000
Investing CF
$124,431,000
Financing CF
$87,964,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.33
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,237,607,000
Inventory
—
Receivables
—
ST Investments
$0
EBIT TTM
$-219,036,000
Pretax Income TTM
$-222,339,000
Interest Exp TTM
$4,637,000
Analysts
8
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -241,156,000 | -236,928,000 | 191,047,000 | 87,176,000 | 103,871,000 | -206,440,000 |
| Dec 2024 | 0 | -263,464,000 | -243,787,000 | 316,972,000 | 29,908,000 | 287,064,000 | -182,936,000 |
| Dec 2023 | 0 | -252,098,000 | -235,925,000 | 496,195,000 | 27,119,000 | 469,076,000 | -163,278,000 |
| Dec 2022 | 0 | -135,870,000 | -130,904,000 | 426,234,000 | 873,084,000 | -446,850,000 | -114,896,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$9,575,000
NetIncome TTM
$-222,394,000
OpCashFlow TTM
—
Assets (Latest)
$153,877,000
Forward EPS
$-0.67
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CLLS | Cellectis S.A. | $90.90M | $1.25 | — |
| ATRA | Atara Biotherapeutics, Inc. | $92.65M | $9.23 | — |
| CGTX | COGNITION THERAPEUTICS INC | $85.13M | $0.90 | — |
| CRDF | Cardiff Oncology, Inc. | $82.46M | $1.06 | — |
| PTHS | Pelthos Therapeutics Inc. | $78.48M | $20.50 | — |
News headlines (Yahoo Finance, 1h cache)
Biotech Options Buzz: UTHR, NMRA, EWTX
2026-09-18 15:46 · Yahoo
Neumora Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-08-14 11:00 · Yahoo
Neumora Therapeutics Reports Favorable NMRA-215 Toxicology Results with Planned Clinical Advancement in 2026
2026-07-27 11:00 · Yahoo
Neumora Therapeutics (NMRA) Stock Sees Fair Value Falls After Navacaprant Discontinuation
2026-07-11 15:08 · Yahoo
Why Neumora Therapeutics, Inc. (NMRA) Is One of the Best Get Rich Quick Stocks to Buy
2026-07-07 05:53 · Yahoo
Why Neumora Therapeutics (NMRA) Faces a Major Catalyst From Navacaprant’s Upcoming Depression Data
2026-06-17 15:17 · Yahoo
Three pivotal MDD trial failures for Neumora lead to staffing cuts
2026-06-16 15:58 · Yahoo
Neumora depression drug fails; EnGene to cut 50% of staff
2026-06-16 09:08 · Yahoo
NMRA Stock On Track For Worst Day In 1.5 Years — Neumora Therapeutics' Lead Depression Drug Fails Late Stage Trials
2026-06-15 17:21 · Yahoo
Neumora Ends Depression Drug Programme and Announces Workforce Reduction (NMRA)
2026-06-15 13:28 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.